BioSpace News Archive

KYM-001 causes potent and selective IRAK4 protein knockdown and regression of OCI-LY10 tumor xenografts, both alone and in combination with BTK inhibition

BIOQuébec and BioTalent Canada have announced a collaboration agreement to facilitate access to human resources services specific to life sciences and biotech for all Quebec companies working in that sector.

Company leverages technology from defense/aerospace industries to automate and speed time-consuming tasks; helps healthcare providers succeed under Value-Based Care

The newly expanded CAB will support Cortexyme as its lead investigational gingipain inhibitor, COR388, moves through phase 2/3 clinical development as a potential treatment for patients with mild to moderate Alzheimer’s disease.

INVO Bioscience, Inc. (OTCQB: IVOB), a medical device company which was granted FDA clearance for the first Intravaginal Culture System, INVOcell®, announced the recent appointment of Pressly Ahammed as INVO Bioscience’s new Director of International Business Development.

New Moms’ Healthy Returns offers employers a single-source, comprehensive and customizable solution for working moms

PPD-SNBL, the joint venture of Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), and Shin Nippon Biomedical Laboratories Ltd., one of the largest clinical development service providers in Japan, has been named a top-five growth business and desirable employer by Randstad Japan.

ReNetX Bio, Inc., a leading biotechnology company committed to reversing disease and damage for patients suffering from central nervous system disorders, has announced that the U.S. Food and Drug Administration (FDA) has allowed the Company’s Investigational New Drug (IND) application for its lead drug candidate, fusion protein AXER-204.

Medison Biotech (1995) Ltd. (“Medison”), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX:GUD) (“Knight” or the “Company”), today issued the following open letter from Medison CEO Meir Jakobsohn on Knight’s continued underperformance and conflicts of interest:

Harvard Business School (HBS) and Harvard’s Graduate School of Arts and Sciences (GSAS) announced today a new joint master’s degree program that aims to prepare future leaders at the interface of life sciences and business